ATBECHDEDKESFRGBGRITLILUNLSEMCPTIE......FI....CY................................*JDIM360 (Ver 1.5 21 Nov 2005) - 2999001/00988059CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120060301W173deBibliographieenBibliographyfrBibliographieEP98929555.5199806151999120320020918enenen971237019970614GB2006030120060920000329200013200512072005492005031720060301200609A61K 47/48 19900101AFI20050303BHEP A61P 35/00 20000101ALI20050303BHEP A61K 38/44 19950101ALI20050303BHEP A61K 31/4422 20000101ALI20050303BHEP deMENSCHLICHE CHINON REDUKTASE KONJUGATE FÜR ADEPT UND GDEPTenHUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPTfrCONJUGES DE QUINONE-REDUCTASE HUMAIN POUR ADEPT ET GDEPTWO-A-93/08288WO-A-95/12678WO-A-97/07097WO-A-97/24143WO-A-98/22577KNOX R J ET AL: "THE BIOACTIVATION OF CB 1954 AND ITS USE AS A PRODRUG IN ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT)" CANCER AND METASTASIS REVIEWS, vol. 12, no. 2, 1993, pages 195-212, XP000618513 cited in the applicationFRIEDLOS F ET AL: "METABOLISM OF NADPH BY BLOOD COMPONENTS RELEVANCE TO BIOREDUCTIVELY ACTIVATED PRODRUGS IN A TARGETED ENZYME THERAPY SYSTEM" BIOCHEM PHARMACOL, vol. 44, no. 4, 1992, pages 631-635, XP000618526 cited in the applicationWU K ET AL: "Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase." ARCH BIOCHEM BIOPHYS, NOV 15 1997, 347 (2) P221-8, XP002080156 UNITED STATESMELTON, R. G. ET AL: "Antibody-directed enzyme prodrug therapy (ADEPT). Review article" DRUGS OF THE FUTURE, vol. 21, no. 2, 1996, pages 167-184, XP002080157SHERWOOD R F: "ADVANCED DRUG DELIVERY REVIEWS: ENZYME PRODRUG THERAPY" ADVANCED DRUG DELIVERY REVIEWS, vol. 22, 1996, pages 269-288, XP002064128GREEN N. K. ET AL: "Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene" CANCER GENE THERAPY, vol. 4, no. 4, August 1997, pages 229-238, XP002092056DRABEK D. ET AL: "The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954" GENE THERAPY, vol. 4, no. 2, February 1997, pages 93-100, XP00209205704076964.8146869820040707BURKE, Philip, John45 Elliscombe Road, CharltonLondon SE7 7PFGBKNOX, Richard, John21 Cypress Court, Cheam RoadSutton, Surrey SM1 2SUGBProtherics Molecular Design Limited07210350ENZM/P19133EPThe Health Business and Technical ParkRuncorn Cheshire WA7 4QFGBMiles, John Stephen00086141Eric Potter Clarkson LLP Park View House 58 The RopewalkNottingham NG1 5DDGBATBECHCYDEDKESFIFRGBGRIEITLILUMCNLPTSEGB199800173119980615enWO19980576621998122319985119990812000000